Tumor necrosis factor alpha (TNF) is a known mediator of inflammation and pain associated with radiculopathy and intervertebral disc (IVD) degeneration. Soluble TNF receptors (sTNFR) and their analogues are of interest for the clinical treatment of these IVD pathologies although information on the effects of sTNFR on human IVD cells remains unknown. The objective of this study was to investigate an ability for soluble TNF receptor type II (sTNFRII) to antagonize TNF induced inflammatory events in primary human IVD cells in vitro. IVD cells were isolated from surgical tissues procured from 15 patients and cultured with or without 1.4 nM TNF25ng/ml). Treatment groups were co-incubated with varying doses of sTNFRII (12.5-100nM). Nitric oxide (NO), prostaglandin E 2 (PGE 2 ), and interleukin-6 (IL6) levels in media were quantified to characterize the inflammatory phenotype of the IVD cells.
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Introduction
Tumor necrosis factor (TNF) is one of several pro-inflammatory cytokines believed to contribute to the painful symptoms and progressive pathology of intervertebral disc (IVD) disorders, including disc degeneration, disc herniation and lumbar or cervical radiculopathy [1] [2] [3] [4] . TNF is spontaneously produced by IVD tissues ex vivo [5, 6] , is expressed at higher levels in herniated IVD tissues from symptomatic patients compared to asymptomatic or autoptic controls, and its expression levels increase with increasing radiographic grade of degeneration in the IVD [1, 7, 8] . Macrophages are key producers of TNF and their increased presence in herniated and degenerated IVD tissues has been suggested as one of several sources in the IVD [9] [10] [11] [12] .
Cells of the IVD respond to proinflammatory stimuli (TNF, lipopolysaccharide (LPS), and interleukin-1 beta (IL-1) in vitro with a net catabolic response characterized by decreased collagen and aggrecan synthesis, increased gene or protein expression for degradative collagenases, gelatinases and aggrecanases, as well as increased release of inflammatory mediators, such as nitric oxide (NO), prostaglandin E 2 (PGE 2 ), and interleukin-6 (IL6) [2, 5, 11, [13] [14] [15] [16] . TNF exposure can also promote nerve growth factor (NGF) and NGF receptor expression in primary IVD cells in vitro [17] . Exogenous TNFα placed on dorsal root ganglia can induce decreased nerve conduction velocities [6, 18] and increased mechanical allodynia and thermal hyperalgesia characteristic of IVD herniation in rat models [18, 19] , which suggests a potential role for TNF in regulating pain-related IVD pathology. Together, these studies have motivated interest in developing and characterizing therapies able to antagonize the inflammatory and catabolic events associated with TNF exposure in the IVD [20] [21] [22] [23] [24] .
While TNFα binds multiple receptors, two cell surface receptors, TNF receptors (TNFR) type I and II, are the most abundant and potent receptors for stimulating multiple apoptotic and pro-inflammatory pathways [25, 26] . The molecular basis of TNFα signaling is complex and depends on cell lineage, but is known to involve the activation of NF-B, AP-1, and MAPK transduction factors in IVD cells [15, 16] . Both p38 MAPK [14] and NF-B inhibitors [27] have been studied as therapeutic targets for antagonizing intracellular effects of TNF in IVD cells, and two anti-proliferative antibiotics, minocycline [28, 29] and pentoxifylline [6] , have been evaluated for treating neuropathic pain models in rats. TNF-neutralizing antibodies have also been examined for mediating inflammation in IVD tissues in vitro [30] , evaluated in animal models [3, 6, 31, 32] , and clinically for IVD herniation-associated radiculopathy [21] .
Soluble cleavage products of the Type I and Type II TNF receptors (sTNFRI and sTNFRII respectively) retain a high affinity for TNFα [33] and function as decoy binding sites for this cytokine [34, 35] . TNFα activity can hence be antagonized by sequestering soluble TNFα away from target receptors or by interacting with membrane-associated TNFα that will promote cytokine internalization and degradation. Clinical interest in the use of soluble receptors as TNF antagonists has led to the development of sTNFRI and sTNFRII analogues formed by conjugation or fusion to a macromolecular carrier, such as polyethylene glycol (PEG) or immunoglobulin G (IgG) constant domain (pegsunercept [36] ; lenercept [37] and etanercept [38] ). Clinical trials of systemic administration of etanercept, a sTNFRII:IgG fusion protein [38] , have been conducted with the hope of reducing symptoms associated with lumbar radiculopathy [22, 23] . While these and prior studies have shown interest in use of soluble TNF receptors or TNFblocking antibodies for mediating nerve root-associated radiculopathy, data on the direct biological effects of sTNFR on IVD cells challenged with TNF is not available. The objective of this study was to characterize the inflammatory response of human primary IVD cells following TNF stimulation and test for a dose-dependent attenuation of these effects with sTNFRII.
Methods
Isolation of human IVD cells
Pathologic intervertebral disc tissues were obtained according to IRB approved protocols from 15 different patients undergoing surgery for treatment of degeneration or adult scoliosis (n=15). Tissues were procured from levels between L1 and L5 in patients ranging from 14 to 74 years of age. Regions corresponding to anulus fibrosus and nucleus pulposus were mechanically separated where possible, and only anulus fibrosus cells were isolated via enzymatic digestion as described previously [39] (0.3% pronase (HyClone, Thermo Scientific, Waltham, MA, USA), 100 U/ml penicillin and 100 g/ml streptomycin, 10 mM HEPES, 1 g/ml Fungizone) and allowed to grow to confluence with a change of culture medium every 2-3 days. Cells for all experiments were used within 2 passages of culture after isolation.
Cell stimulation with TNF and sTNFRII
Cells were seeded in gelatin-coated wells of 48-well plates (50,000 cells/well; 3
replicates per treatment group per patient sample), overlaid with 300l of culture medium, and allowed to attach for 24hrs. Fresh culture medium (300l) supplemented with 1.4 nM rhF (Abcam, Cambridge, MA, USA; 25 ng/ml; 17.4 kDa) was added to attached cells; control cells received an exchange of culture medium without F.
Cells in one of four treatment groups were co-treated with rh-sTNFRII (Abcam;
18.9kDa) at 12.5, 25, 50, or 100 nM, which was added at the same time as TNF. The dose of TNF was chosen to elicit a large enough inflammatory response such that attenuation with sTNFRII could be easily detected over a range of drug doses. All cells were cultured at 37C and 5% CO 2 for an additional 72 hrs and supernatants were collected at the termination of all experiments and stored at -20C until quantitation.
Quantitation of inflammatory mediators
All supernatants for each patient were assayed for release of NO (Griess reaction) [40] , PGE 2 (ELISA, R&D Systems, Minneapolis, MN, USA), and IL6 (ELISA, R&D Systems). Standard curves for ELISAs were generated as prescribed by the manufacturer, and absorbance values of standards for NO quantitation were adjusted for the absence of culture medium.
Values for each inflammatory mediator in culture medium only were quantified and averaged across 3 replicates for each assay; this mean value was subtracted from corresponding data for each assay. A fold change from control (i.e., cells receiving no 
Statistical analyses
where X is the attenuation fraction of inflammatory mediator present relative to TNF only controls, X min is the minimal observed fraction, and X max is the maximal observed fraction upon stimulation with TNF. The Hill slope, k, and b are fit parameters. Mean values for the normalized concentration of each inflammatory mediator for each patient were used to determine patient-specific IC 50 , and average values across all patients were reported. Outlier values for each mediator were not used in determination of IC 50 .
Goodness of fit was reported as the coefficient of determination, R 2 ; and upper and lower bounds of the 95% confidence interval were graphically generated.
Results
Human IVD cell response to TNF
Across all patients, TNF (1.4 nM; 25ng/ml) induced a very large and statistically significant increase in release of NO, PGE 2 , and IL6 (Table 1) ). *Calculated after removing outliers, as determined from box plot (Figure 1 ).
Attenuation of TNF-induced inflammatory events
Coincubation with sTNFRII significantly abated TNF-induced release of NO and PGE 2 from human IVD cells in a dose-dependent manner (Figure 2) . In contrast, TNF-induced release of IL6 was not attenuated by sTNFRII. Antagonist treatment Attenuation of IL6 release followed an unexpected behavior for some patients.
To investigate these results, sTNFRII (50 nM) without F was also added to cells from 5 individual patients and cultured for the same period of time under the same conditions. Surprisingly, the presence of sTNFRII alone at a concentration of 50nM induced a significant release of IL6 (1.41 ± 0.04 fold-change; mean ± SEM) from human IVD cells (n=5), but did not affect NO or PGE 2 release. This finding could explain the inability of sTNFRII to significantly moderate TNF-induced release of IL6. 
Discussion
The primary objective of this study was to investigate an ability for sTNFRII to antagonize TNF induced inflammatory events in primary human IVD cells in vitro.
Across all patients, TNF induced large, statistically significant increases in NO, PGE 2 , and IL6 secretion from IVD cells compared to controls. For the sample population tested, there was no detected effect of patient age on release of NO, PGE 2 , or IL6.
Coincubation of TNF with nanomolar doses of sTNFRII significantly attenuated the secretion of NO and PGE 2 in a dose-dependent manner. TNF-induced secretion of IL6, however, was unchanged by the same concentrations of sTNFRII, a result that may be explained by a statistically significant induction of IL6 by sTNFRII without TNF for a subset of patients. Attenuation data was fit to nonlinear regression models to calculate IC 50 values for NO and PGE 2 release for each patient. Mean IC 50 values for NO and PGE 2 were found to be 24.0 ± 9.0 nM and 29.0 ± 9.0 nM, respectively (mean ± SEM),
indicating that nanomolar concentrations of sTNFRII were able to significantly attenuate the effects of TNF on primary human IVD cells in vitro.
Pathologic IVD tissue is known to exhibit an inflammatory phenotype characterized by infiltrating innate and adaptive immune cells, along with their proinflammatory chemokine products. Herniated and degenerate IVD tissue contain significantly higher levels of TNF [1, 7] , and TNF is known to be a key mediator of pain and inflammation associated with radiculopathy following herniation [3, 6, 18, 31, 32] .
Our observed trends of increased secretion of key inflammatory mediators, NO, PGE 2 , and IL6, from pathologic primary human IVD cells after exposure to TNF corroborate previous reports of human nucleus pulposus (NP) cells cultured in alginate [14] . Studer et al. [14] challenged human NP cells in vitro with TNF, at a lower dose of 5 ng/ml, and also saw significant increases in NO, PGE 2 , and IL6 secretion after 72 hours in culture.
While induced secretion trends are similar to those reported here, differences in cell type, culture method, and dose of TNF likely contribute to differences in absolute cell responses. A higher dose of TNF used in this study was chosen to allow for higher resolution of the expected antagonistic effect of sTNFRII.
Quantitation of attenuation with sTNFRII revealed that low concentrations of sTNFRII were able to significantly attenuate TNF effects, which further supports claims Soluble TNF receptor-based therapies provide the benefits of high affinity and low molecular weight for designing locally delivered, sustained release systems for treating IVD pathologies [42, 43] .
TNFis likely not the only mediator of pathology in the IVD, with some data indicating a more crucial role for IL-1 in initiating matrix catabolism and IVD degeneration [30] . However, the robust inflammatory response of pathologic IVD cells to TNF reported herein supports previous findings [2, 7, 11, 13, 15, 16] and motivates continued interest in targeting TNF for treating IVD pathologies. In this study, nanomolar concentrations of sTNFRII conferred a potent antagonistic effect on TNF-induced secretion of NO and PGE 2 in vitro, but did not attenuate IL6 release.
Interestingly, intracellular antagonism of TNF with a p38 MAPK inhibitor [14] had a statistically significant effect on PGE 2 and IL6, but had no effect on NO, whereas we observed effects on NO and PGE 2 , but not IL6 secretion, using an extracellular-acting antagonist. Blocking the TNF signaling cascade before TNFR activation, as done here, would suggest that differences in intracellular signaling cascade upregulation for these mediators only partly contribute to differences in our findings for IL6. Rather, sTNFRII may be interacting with another membrane-bound component of pathologic IVD cells, such as membrane bound TNF, and lead to the activation of cascades specific to IL6, but not NO or PGE 2 upregulation. Future studies utilizing separate intracellular signaling pathway inhibitors may elucidate differences in regulatory mechanisms between NO, PGE 2 , and IL6, as well as the unexpected effect of sTNFRII on IL6. The effect of TNF on matrix-degrading enzymes of the IVD was not measured in this study, but may be worth pursuing in future studies, as the net catabolic activity of these enzymes plays a crucial role in disc degeneration and reversal of this activity would be beneficial clinically.
NO, PGE 2 , and IL6 are known to have pro-and anti-inflammatory activities in osteoarthritis models and articular chondrocytes [44] , but these cytokines' exact roles in IVD pathologies require further definition. Herniated IVD specimens have been shown to produce NO, PGE 2 , and IL6 [5, 45] , as well as a host of other inflammatory mediators [11, 13] , spontaneously in vitro or after stimulation with proinflammatory cytokines. Nitric oxide has been shown to mediate the change in proteoglycan synthesis in human IVD explants in response to hydrostatic pressure [46] , as well as pain-related behavior in a rat model of radiculopathy [47] . PGE 2 is a product of cyclooxygenase-2 (COX-2) activity, an enzyme implicated in the pathology of IVD herniation [48, 49] , and epidural injection of a COX-2 inhibitor for treating a rat radiculopathy model significantly alleviated mechanical allodynia [50] . IL6 may play a role in activating or attracting glial cells to sites of nerve injury [51] , or may be a key inflammatory product of glial cells recruited to some nerve root injuries [52] . Some association between IL6
protein levels and painful manifestations of disc degeneration, but not normal disc physiology, has been demonstrated [11] . Interestingly, in one rat radiculopathy model, IL6 protein levels were observed to increase following local delivery of a pharmacologic cocktail of IL-1 receptor antagonist and sTNFRI [51] . This finding mirrors our own observations of increased IL6 induction by sTNFRII without TNF by primary IVD cells and may imply a similar mechanism persists for other relevant cell types of this pathology. While the roles of NO, PGE 2 , and IL6 are not entirely clear, they each represent good measures of inflammation in response to TNF. The substantially greater release of NO and PGE 2 from our studies (Figure 1 ) suggests these two inflammatory mediators may be better readouts for evaluating new TNF antagonists in vitro.
Conclusion
Human primary IVD cells responded to TNFin vitro by releasing large, statistically significant levels of NO, PGE2, and IL6 compared to controls. We report in vitro evidence of the effects of sTNFRII on pathologic IVD cells stimulated with TNF, wherein nanomolar doses of sTNFRII were able to significantly attenuate TNF-induced secretion of key inflammatory mediators. These findings highlight the importance of targeting TNF in inflammatory pathologies of the IVD and emphasize the value of using soluble TNF receptors, and their analogues, to treat such pathologies. Any future TNF antagonists and related drug delivery formulations for treating IVD pathologies may benefit from the IC 50 data reported herein as a metric for evaluating new drug performance and bioactivity before proceeding to pre-clinical animal models.
